tetano
Editor, Senior Moderator
Eur Heart J Cardiovasc Pharmacother
. 2020 Sep 10;pvaa105.
doi: 10.1093/ehjcvp/pvaa105. Online ahead of print.
Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues
Silvia Fogacci, Federica Fogacci[SUP] 1 [/SUP], Elda Favari[SUP] 2 [/SUP], Peter P Toth[SUP] 3 [/SUP], Claudio Borghi[SUP] 1 [/SUP], Arrigo F G Cicero[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus-19 disease (COVID-19) continues to spread throughout the world. It is known that among patients with hypertension, diabetes, chronic respiratory disease, or cardiovascular diseases, COVID-19 is associated with greater morbidity and mortality compared with patients without these conditions. This correlation is of great importance in pregnant women affected by COVID-19, since it usually leads to the development of a serious clinical complication. In particular, managing hypertensive disorders in pregnancy can be problematic because antihypertensive medications may interact pharmacologically with drugs used to treat COVID-19. This review focuses on the safety of drug treatment for COVID-19 in pregnant women treated with antihypertensive medication. Several databases were searched to identify relevant literature. A few antihypertensive drugs and antithrombotic treatments are known for having a beneficial effect in the management of hypertension and hypertensive disorders in pregnancy. In this review, we focus on the expected drug-drug interactions with the experimental agents most often used to treat COVID-19. The current indications for the management of hypertension-related disorders in pregnancy maintain their validity, while the risk of pharmacological interaction with the currently tested anti-SARS-CoV-2 medications is relatively low.
Keywords: Antihypertensive treatment; COVID-19; Coronavirus-19; Hypertension; Pregnancy; SARS-CoV-2.
. 2020 Sep 10;pvaa105.
doi: 10.1093/ehjcvp/pvaa105. Online ahead of print.
Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues
Silvia Fogacci, Federica Fogacci[SUP] 1 [/SUP], Elda Favari[SUP] 2 [/SUP], Peter P Toth[SUP] 3 [/SUP], Claudio Borghi[SUP] 1 [/SUP], Arrigo F G Cicero[SUP] 1 [/SUP]
Affiliations
- PMID: 33155016
- DOI: 10.1093/ehjcvp/pvaa105
Abstract
Coronavirus-19 disease (COVID-19) continues to spread throughout the world. It is known that among patients with hypertension, diabetes, chronic respiratory disease, or cardiovascular diseases, COVID-19 is associated with greater morbidity and mortality compared with patients without these conditions. This correlation is of great importance in pregnant women affected by COVID-19, since it usually leads to the development of a serious clinical complication. In particular, managing hypertensive disorders in pregnancy can be problematic because antihypertensive medications may interact pharmacologically with drugs used to treat COVID-19. This review focuses on the safety of drug treatment for COVID-19 in pregnant women treated with antihypertensive medication. Several databases were searched to identify relevant literature. A few antihypertensive drugs and antithrombotic treatments are known for having a beneficial effect in the management of hypertension and hypertensive disorders in pregnancy. In this review, we focus on the expected drug-drug interactions with the experimental agents most often used to treat COVID-19. The current indications for the management of hypertension-related disorders in pregnancy maintain their validity, while the risk of pharmacological interaction with the currently tested anti-SARS-CoV-2 medications is relatively low.
Keywords: Antihypertensive treatment; COVID-19; Coronavirus-19; Hypertension; Pregnancy; SARS-CoV-2.